Review of U.S. Coast
Guard's Fiscal Year 2021
Detailed Accounting
Report for Drug Control
Funds





### OFFICE OF INSPECTOR GENERAL

# Department of Homeland Security

Washington, DC 20528 / www.oig.dhs.gov

January 28, 2022

MEMORANDUM FOR: Admiral Karl L. Schultz

> Commandant U.S. Coast Guard

FROM: Joseph V. Cuffari, Ph.D.

Inspector General

JOSEPH V

Digitally signed by JOSEPH V CUFFARI

Date: 2022.01.27 16:17:28

CUFFARI

Review of U.S. Coast Guard's Fiscal Year 2021 Detailed SUBJECT:

Accounting Report for Drug Control Funds

Attached for your information is our final report, Review of U.S. Coast Guard's Fiscal Year 2021 Detailed Accounting Report for Drug Control Funds. U.S. Coast Guard (USCG) management prepared the Table of FY 2021 Drug Control Obligations and related assertions to comply with the requirements of the Office of National Drug Control Policy Circular, National Drug Control Program Agency Compliance Reviews, dated September 9, 2021.

We contracted with the independent public accounting firm Williams, Adley & Company – DC, LLP (Williams Adley) to review USCG's Detailed Accounting Report. Williams Adley is responsible for the attached Independent Accountant's Report, dated January 19, 2022, and the conclusions expressed in it. Williams Adley's report contains no recommendations.

Consistent with our responsibility under the *Inspector General Act of 1978*, as amended, we will provide copies of our report to congressional committees with oversight and appropriation responsibility over the Department of Homeland Security. We will post the report on our website for public dissemination.

Please call me with any questions, or your staff may contact Bruce Miller, Deputy Inspector General for Audits at (202) 981-6100.

Attachment

cc: COMDT (CG-8), USCG

# **DHS OIG HIGHLIGHTS**

Review of U.S. Coast Guard's Fiscal Year 2021
Detailed Accounting Report for Drug Control Funds

January 28, 2022

# Why We Did This Review

The Office of National Drug
Control Policy (ONDCP)
Circular, National Drug
Control Program Agency
Compliance Reviews,
requires National Drug
Control Program agencies to
submit to the ONDCP
Director by February 1 each
year a detailed accounting of
all funds expended for
National Drug Control
Program activities during the
previous fiscal year.

At least every 3 years, the Office of Inspector General is required to review the agency's submission and provide a conclusion about the reliability of each assertion in the report.

#### For Further Information:

Contact our Office of Public Affairs at (202) 981-6000, or email us at DHS-OIG.OfficePublicAffairs@oig.dhs.gov

# What We Found

Williams, Adley & Company – DC, LLP (Williams Adley), under contract with the Department of Homeland Security Office of Inspector General, issued an Independent Accountant's Report on U.S. Coast Guard's (USCG) Detailed Accounting Report. USCG management prepared the Table of FY 2021 Drug Control Obligations and related assertions to comply with the requirements of the ONDCP Circular, *National Drug Control Program Agency Compliance Reviews*, dated September 9, 2021.

Based on its review, nothing came to Williams Adley's attention that caused it to believe that the Coast Guard's FY 2021 Detailed Accounting Report and related assertions are not presented in conformity with criteria in the Circular. Williams Adley did not make any recommendations as a result of its review.

www.oig.dhs.gov OIG-22-24



#### **Independent Accountant's Report**

Inspector General
United States Department of Homeland Security

We have reviewed the accompanying Detailed Accounting Report (DAR) of the U.S. Department of Homeland Security's (DHS) United States Coast Guard (USCG) for the year ended September 30, 2021. USCG management is responsible for the preparation of the DAR in conformity with the requirements of the Office of National Drug Control Policy Circular: *National Drug Control Program Agency Compliance Reviews*, dated September 9, 2021 (the Circular). Our responsibility is to express a conclusion about management's assertions based on our review.

Our review was conducted in accordance with the attestation standards established by the American Institute of Certified Public Accountants and generally accepted government auditing standards. Those standards require that we plan and perform the review to obtain limited assurance about whether any material modifications should be made to the DAR or related assertions in order for them to be in accordance with the Circular. A review is substantially less in scope than an examination, the objective of which is to obtain reasonable assurance about whether USCG's DAR and related assertions are in accordance with the Circular, in all material respects, in order to express an opinion. Accordingly, we do not express such an opinion. We believe that our review provides a reasonable basis for our conclusion.

Based on our review, we are not aware of any material modifications that should be made to the DAR or related assertions for the year ended September 30, 2021, in order for them to be in conformity with the requirements set forth in the Circular.

This report is intended solely for the information and use of DHS Office of Inspector General, USCG, and the Office of National Drug Control Policy, and is not intended to be, and should not be, used by anyone other than the specified parties.

Washington, D.C. January 19, 2022

Williams, Adly & Compuy-DC, LLP



2703 Martin Luther King Jr. Ave. SE Washington, DC 20593 Staff Symbol: CG-821 Phone: (202) 372-2307

7110

JAN 19 2622

Regina M. LaBelle Office of National Drug Control Policy 750 17<sup>th</sup> Street, NW Washington, DC 20503

Dear Ms. LaBelle,

In accordance with the Office of National Drug Control Policy Circular: *Budget Formulation*, issued September 9, 2021, enclosed is the Coast Guard's FY 2021 Detailed Accounting Report.

If there are any questions, please contact my Drug Budget Coordinator, LCDR Ben Leuthold, (202) 372-2307.

Sincerely,

Captain, U.S. Coast Guard

Chief, Office of Budget and Programs

Enclosures: (1) USCG FY 2021 Detailed Accounting Report

Copy: Department of Homeland Security, Office of the Chief Financial Officer, Budget

Division

# DEPARTMENT OF HOMELAND SECURITY UNITED STATES COAST GUARD Detailed Accounting Report of FY 2021 Drug Control Funds

#### DETAILED ACCOUNTING REPORT

# 1. Table of FY 2021 Drug Control Obligations

# RESOURCE SUMMARY

2021 Actual

(Donars in Willions)	2021 Actual
Drug Resources by Drug Control Function:	Obligations
Interdiction	\$1,984.500
Research and Development	\$1.149
Total Resources by Function	\$1,985.649
Drug Resources by Budget Decision Unit:	
Operations and Support (O&S)	\$1,310.857
Procurement, Construction, and Improvements (PC&I)	\$673.643
Research and Development (R&D)	\$1.149
Total Drug Control Obligations	\$1,985.649

# 2. **Drug Methodology**

In fiscal year (FY) 2000, a methodology known as the Mission Cost Model (MCM) was developed to present the United States Coast Guard (USCG) missions using activity-based cost accounting principles. The MCM is an estimate of operational mission costs allocated across the Coast Guard's 11 missions/programs consisting of: Drug Interdiction; Migrant Interdiction; Ports, Waterways and Coastal Security; Other Law Enforcement; Defense Readiness; Search and Rescue; Marine Safety; Ice Operations; Marine Environmental Protection; Living Marine Resources; and Aids to Navigation. The MCM output allocated to Drug Interdiction is allocated to the Office of National Drug Control Policy (ONDCP) Drug Control Function 'Interdiction' for all decision units with the exception of R&D. R&D is allocated to ONDCP Control Function 'Research and Development'. The information reported is timely and derived from an allocation process involving the Coast Guard's financial statement information and operational employment data. The operating hour allocation, or baseline, is developed and modified based upon budget line item requests and operational priorities.

The USCG is required to report its drug control funding to the ONDCP in three appropriations, categorically called decision units. The Coast Guard's drug control funding estimates are computed by examining the decision units that are comprised of: Operations and Support (O&S); Procurement, Construction, and Improvement (PC&I); and Research and Development, (R&D). Each decision unit contains its own unique spending authority and methodology. For example, PC&I includes funding that remains available for obligation up to five years after appropriation and R&D includes funding the remains available for obligation up to three years after appropriation. Unless stipulated by law, O&S funding must

be spent in the fiscal year it is appropriated. The mechanics of the MCM methodology used to derive the drug control information for each decision unit's drug control data is derived as follows.

#### **Mission Cost Allocations**

O&S funds are used to operate Coast Guard facilities, maintain capital equipment, improve management effectiveness, and recruit, train, sustain, and compensate an active duty military and civilian workforce. The Coast Guard tracks resource hours spent on each of its 11 statutory missions. Obligations within the drug interdiction program are derived by allocating a share of the actual obligations of assets and activities based upon the reported percentage of time aircraft, cutters, and boats spent conducting drug interdiction activities.

The two chief input drivers to the MCM are:

- The Coast Guard's Expanse Allocation Model (EAM) The EAM model development, formerly known as the Standard Rate and User Fee Model, uses the SAS® Activity Based Model (ABM) and Enterprise Guide (EG) software solutions. The model inputs include expenditure data captured by the Coast Guard's three general ledgers: Core Accounting System (CAS), Naval and Electronics Supply System (NESSS), and Aircraft Logistics Information Management System (ALMIS). As such, this model calculates the total cost, including direct, support, and overhead, of operating the Coast Guard's assets, as well as missions or services that the Coast Guard performs but does not have related standard rates or user fees.
- Abstract of Operations (AOPS) and ALMIS The Coast Guard tracks resource hours incurred on each
  of the 11 Coast Guard statutory missions using AOPS and ALMIS. This data is then used to determine
  the amount of time each asset class is employed conducting each Coast Guard mission as a ratio of
  total resource hours incurred on all missions.

Using data recorded in the three general ledgers (CAS, NESSS, and ALMIS) in combination with asset activity data recorded in AOPS and ALMIS, the Coast Guard allocates O&S costs to each of the 11 statutory missions. By design, the MCM is based on the O&S decision unit. PC&I and R&D decision units must be calculated separately, due to the structure of the PC&I and R&D decision units, which are presented as individual projects in the Coast Guard's budget submission. Within PC&I and R&D, individual projects are allocated to missions based on an established profile (largely based on utilization). The drug interdiction attributions of each of these projects are then combined to determine the total contribution to the drug interdiction mission.

The program percentages derived from the MCM are applied to O&S, PC&I, and R&D decision units per the above methodology (see Attachments A, B, and C, respectively). Obligation data is derived from the final financial accounting Report on Budget Execution (SF-133).

As previously discussed, because the USCG budgets through congressionally established appropriations (rather than individual missions), the organization must rely on information contained within the activity based MCM. USCG uses this MCM data to determine financial obligations specifically related to statutory missions, including Drug Interdiction. This appropriation structure supports multi-mission requirements by allowing the service to surge and shift resources across all missions. This level of resource flexibility is critical to successful mission execution in our dynamic, operational environment. However, such a structure makes it difficult to precisely determine the cost of a particular mission or the "level of effort"

expended in carrying out in each mission. The MCM provides the USCG with a reliable, repeatable system that forecasts future year spending and estimates previous year obligations by mission.

#### 3. Methodology Modifications

The methodology described above is consistent with the previous year.

#### 4. Material Weaknesses or Other Findings

In prior fiscal years and FY21, the USCG contributed to DHS material weaknesses in the following internal control areas: Financial Reporting and Information Technology Controls and Information Systems. Following the recommendations providing in the previous DHS Independent Auditors' Reports, the USCG has continued to implement corrective action plans to remediate long-standing internal control deficiencies, strengthen existing internal controls, and provide assurance over the fidelity of financial information.

The USCG's control deficiencies that contributed to the department-level material weaknesses did not impair USCG's ability to report complete and accurate obligation data in the Table of FY 2021 Drug Control Obligations. The USCG control deficiencies that contributed to the material weaknesses in Financial Reporting and IT Controls and System Functionality were related to the USCG's three accounting systems. However, the deficiencies were primarily related to access controls, and the USCG had sufficient compensating controls in place to ensure that budgetary data (i.e. obligations) was presented fairly, in all material respects.

# 5. Reprogrammings or Transfers

During FY 2021, USCG had reprogrammings and transfers. As a component of DHS, the USCG submits all reprogramming and transfer requests through the Department for approval, and the impact of these changes to funding is assessed by the Department. In FY 2021, the Department determined there were no reprogrammings or transfers that materially impacted USCG's drug-related obligations reported in the Table of FY 2021 Drug Control Obligations.

#### 6. Other Disclosures

The following provides a synopsis of the USCG's FY 2021 Drug Control Funds reporting which describes:

- 1. The agency's overall mission and the role of drug interdiction efforts within the USCG's multimission structure; and
- 2. The USCG's Drug Budget Submission.

#### Coast Guard Missions

The USCG is a military service with mandated national security and national defense responsibilities, and is the United States' leading maritime law enforcement agency with broad, multi-faceted jurisdictional authority. Due to the multi-mission nature of the USCG and the necessity to allocate the effort of a finite amount of assets, there is a considerable degree of asset "cross-over" between missions. This cross-over contributes to the complexities the USCG faces when reporting costs for its mission areas.

#### **Coast Guard's Drug Budget Submission**

In the annual National Drug Control Strategy (NDCS) Budget Summary, all agencies present their drug control resources broken out by function and decision unit. The presentation by decision unit is the one that corresponds most closely to the USCG's congressional budget submissions and appropriations. It should be noted and emphasized the USCG does not have a specific appropriation for drug interdiction activities. As such, there are no financial accounting lines for each of the USCG's 11 statutory missions. All drug interdiction operations, capital improvements, and research and development efforts are funded through general USCG appropriations.

The USCG's drug control budget is generally an accurate reflection of the USCG's overall budget. The USCG's O&S appropriation budget request is incremental, focusing on the changes from the prior year base brought forward. The USCG continues to present supplementary budget information through the use of the MCM, which allocates base funding and incremental requests by mission.

This general purpose MCM serves as the basis for developing drug control budget estimates for the O&S appropriations and provides allocation percentages used to develop the drug control estimates for the PC&I and R&D appropriations and the process is repeatable. Similarly, this is the same methodology used to complete the USCG's annual submission to ONDCP.

#### Assertions

## 1) Obligations by Budget Decision Unit

Obligations reported by budget decision unit are consistent with the application of the approved methodology, as required by ONDCP Circular: *Budget Formulation*, Section 7, issued September 9, 2021, for calculating drug control funds against the Coast Guard's accounting system of record.

#### 2) Drug Methodology

The methodology used to produce the drug interdiction funding in this report is reasonable and accurate. This methodology is consistently used by the USCG to develop annual budget year submissions and mission related reports. The criteria associated to this assertion are as follows:

a) Data – The percentage allocation results derived from its MCM methodology are based on the FY 2021 financial and AOPS/ALMIS data, as presented in the USCG's FY 2021 enacted budget submission.

Financial Systems – The MCM uses costs from three general ledgers (GL). These include; the CAS GL, the NESSS GL, and the ALMIS GL. These financial systems yield data that fairly presents, in all material respects, aggregate obligations from which drug-related obligation estimates are derived.

# 3) Application of Drug Methodology

The methodology disclosed in this section was the actual methodology used to generate the drug control obligation funding table required by ONDCP Circular: *National Drug Control Program* 

Agency Compliance Review, issued September 9, 2021. Documentation on each decision unit is provided.

# 4) Material Weakness or other findings

All material weaknesses or other findings by independent sources, which may affect the presentation of prior year drug-related obligations as required by section 7.a(4) have been disclosed.

# 5) Methodology Modifications

No modifications were made to the methodology for reporting drug control resources for the previous year's reporting.

# 6) Reprogrammings or Transfers

During FY 2021, the Coast Guard had no reports of transfers or reprogramming actions affecting drug related budget resources, individually or in aggregate, exceeding \$5 million or 10 percent of a specific program or account included in the National Drug Control Budget (21 U.S.C.§ 1703(c)(4)(A)).

# 7) Fund Control Notices

ONDCP did not issue the Coast Guard a Fund Control Notice for FY 2021.



## OFFICE OF INSPECTOR GENERAL

Department of Homeland Security

# Appendix A Report Distribution

# **Department of Homeland Security**

Secretary
Deputy Secretary
Chief of Staff
Deputy Chiefs of Staff
General Counsel
Executive Secretary
Director, GAO/OIG Liaison Office
Under Secretary, Office of Strategy, Policy, and Plans
Assistant Secretary for Public Affairs
Assistant Secretary for Office of Legislative Affairs

#### U.S. Coast Guard

Commandant Chief Financial Officer Audit Liaison

# Office of Management and Budget

Chief, Homeland Security Branch DHS OIG Budget Examiner

#### Congress

Congressional Oversight and Appropriations Committees

# Office of National Drug Control Policy

Associate Director for Management and Administration

www.oig.dhs.gov OIG-22-24

# **Additional Information and Copies**

To view this and any of our other reports, please visit our website at: www.oig.dhs.gov.

For further information or questions, please contact Office of Inspector General Public Affairs at: <a href="mailto:DHS-OIG.OfficePublicAffairs@oig.dhs.gov">DHS-OIG.OfficePublicAffairs@oig.dhs.gov</a>. Follow us on Twitter at: @dhsoig.



## **OIG Hotline**

To report fraud, waste, or abuse, visit our website at <a href="www.oig.dhs.gov">www.oig.dhs.gov</a> and click on the red "Hotline" tab. If you cannot access our website, call our hotline at (800) 323-8603, fax our hotline at (202) 254-4297, or write to us at:

Department of Homeland Security Office of Inspector General, Mail Stop 0305 Attention: Hotline 245 Murray Drive, SW Washington, DC 20528-0305